Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group. - Wikidata - awgldk - TriplyDB

Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group.

Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group.

http://www.wikidata.org/entity/Q33381940

about

Children's Oncology Group's 2013 blueprint for research: bone tumors New strategies in ewing sarcoma: lost in translation?Finding promiscuous old drugs for new uses.Copy Number Alterations and Methylation in Ewing's Sarcoma.Targeted therapies for advanced Ewing sarcoma family of tumors.Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment The first European interdisciplinary ewing sarcoma research summit Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma 18F-FLT Positron Emission Tomography (PET) is a Pharmacodynamic Marker for EWS-FLI1 Activity and Ewing Sarcoma.Ewing's sarcoma: overcoming the therapeutic plateau.Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.Ewing sarcoma: biology-based therapeutic perspectives.Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.Factors Affecting EWS-FLI1 Activity in Ewing's Sarcoma.Downstream EWS/FLI1 - upstream Ewing's sarcoma Role of Phase 0 trials in drug development.Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine.Advances in the Treatment of Pediatric Bone Sarcomas.Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance.

P2860

Q27027664-D9533FA6-FED2-444D-ACF8-7584B9C0E5EC Q33758471-7161801B-C4E5-45A7-A98B-6F9486B4D19D Q33910025-855B971B-F00A-4100-8D68-C0A2EA9E67B4 Q34700651-99F72427-A930-47A9-A2F7-0B44E9CF3A5E Q35589492-C403EA54-CFDF-4F4B-9EA4-940A91440031 Q35958048-CE10888C-AB9C-4B08-90C7-F137C4A8BB60 Q35993560-C2C99963-F69A-48C0-BC48-7C1BD5E0CDDB Q36038953-426D47B5-358D-465C-A396-A6F4ABB54CDE Q36362320-E1163403-F5EF-4E30-B78C-0491AD6246AA Q36562726-D67E7948-F5CF-4186-BDBF-9A267915BCF2 Q36738866-EE1F8630-C76D-451A-B796-85353F8B1CB5 Q37200438-BCBC1299-9551-4F1B-A552-1613AFA70AFA Q37285365-B0423664-E80F-469E-9297-A62D9F82C5C7 Q37487126-3ED104B1-7D3B-49D1-8B15-6B9B8DED1433 Q37665228-FA0C2991-18EC-4B27-9FFD-E6C109A7F6B6 Q37981253-CC79275F-A0B9-4F25-829E-28B12D3D8034 Q38113988-1C39BC57-37A2-4B17-B7C5-BD4C179F6CB8 Q38243878-CDD83CBD-4CE5-488E-8954-A248CA8C4B4D Q38405404-7C898AA2-6CC8-4C78-95E1-E4FAECCA3174 Q39113281-71AEC95A-7118-481F-BC10-5B813E21A0EC Q39325942-DCA86B52-55CA-4710-8342-57400F06658C Q39934032-526188F9-0B89-4162-B5E0-958FDEF8AFB3 Q41739827-5FD05227-8D63-4BD8-9275-55DD32E6EE60 Q47130816-6F603010-8BF8-45E4-98FC-EEE33535133D Q50969326-67017D4C-EAEB-41B8-BBF6-A301786A22B9 Q51098298-AFA1F15D-331F-4825-98FF-8402F2E071DF

P2860

Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group.

http://www.wikidata.org/entity/Q33381940

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Phase II study of intermediate ...... the Children's Oncology Group.

@ast

Phase II study of intermediate ...... the Children's Oncology Group.

@en

type

label

Phase II study of intermediate ...... the Children's Oncology Group.

@ast

Phase II study of intermediate ...... the Children's Oncology Group.

@en

prefLabel

Phase II study of intermediate ...... the Children's Oncology Group.

@ast

Phase II study of intermediate ...... the Children's Oncology Group.

@en

P1433

Q33381940-1A3C779A-51D7-4BDD-98B6-20676A69C8BF

P1476

Q33381940-A06F7142-8D17-42FA-8417-29BB16707D31

P2093

Q33381940-163EE1DA-5CE1-4C58-8688-A45B3A7D9ABE

Q33381940-4D37F49B-F435-4EEC-852A-9F90BD179FA1

Q33381940-5CD27DE9-7617-4B20-960A-CC6A82F2FD86

Q33381940-7233BAAC-20FA-41F8-8379-A081DDA263DB

Q33381940-73481BAF-6FD1-4A36-9B2A-2B4F2C65D0AC

Q33381940-9CEABA4E-E495-4624-AE11-639850488589

Q33381940-BB8C385D-6DCD-4CCA-A895-BF83BAA0493A

Q33381940-E01137F7-3515-4F06-9146-C57129558624

P2860

Q33381940-0C650C1D-5EFC-4347-A292-406A83C422F9

Q33381940-12FE98FB-1B5C-4B4F-AC37-D43D3F323213

Q33381940-1814DD22-E683-4CF2-BFDE-339EA9442765

Q33381940-297C140D-BD1A-429A-8DA4-6CE39AC3B519

Q33381940-3E14215A-5F71-4182-A7CD-D7C3B3E8F4DE

Q33381940-4C571575-48FA-498A-B03B-5EABF8DBDAA7

Q33381940-50EE88C0-1945-4C21-9EF4-3642E07B064E

Q33381940-5A85ED01-BBBE-4622-9AAF-1CD734460911

Q33381940-628CD615-95B4-4FAD-A1F5-CAB6C651BB17

Q33381940-643A3FD6-317F-4C98-ABD0-07948E634E62

P304

Q33381940-A26C1E0E-A884-424F-B593-E3D934C80358

P31

Q33381940-80B70144-5106-48B1-AA1B-83FFA99F65E6

P356

Q33381940-AB7556F9-E314-4C4F-A30F-22FEBBDA2000

P433

Q33381940-FFCD50FD-E70E-485E-BCD6-C55B45A31D43

P478

Q33381940-FAFF284B-C9B0-44A4-BC1C-CA2606DE6BC6

P50

Q33381940-2D65502A-3152-4A23-9B37-D98A6F12F674

P577

Q33381940-CF5CEE70-2F52-4684-86D8-71086F3BF328

P5875

Q33381940-21C6CD24-84D4-4F02-ADEC-8D9B08CE7582

P698

Q33381940-3FAD5F12-FEEA-4700-921D-C256249C1C72

P932

Q33381940-E3DF0950-F2B1-4DCC-89B0-7750914FED8D

P356

P1433

Pediatric Blood & Cancer

P1476

Phase II study of intermediate ...... the Children's Oncology Group.

@en

P2093

Children's Oncology Group

http://www.w3.org/2001/XMLSchema#string

Holcombe E Grier

http://www.w3.org/2001/XMLSchema#string

Mark D Krailo

http://www.w3.org/2001/XMLSchema#string

Neyssa Marina

http://www.w3.org/2001/XMLSchema#string

Richard Smith

http://www.w3.org/2001/XMLSchema#string

Stephen L Lessnick

http://www.w3.org/2001/XMLSchema#string

Steven G DuBois

http://www.w3.org/2001/XMLSchema#string

Zhengjia Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12)

Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma

Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma.

Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies.

Survival after recurrence of Ewing's sarcoma family of tumors.

Toxicity of high-dose cytosine arabinoside in the treatment of advanced childhood tumors resistant to conventional therapy. A Pediatric Oncology Group study.

Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.

Insulin-like growth factor-I-dependent growth and in vitro chemosensitivity of Ewing's sarcoma and peripheral primitive neuroectodermal tumour cell lines.

P304

324-327

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.21822

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P50

Kimberly Stegmaier

P577

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23457094

http://www.w3.org/2001/XMLSchema#string

P698

18989890

http://www.w3.org/2001/XMLSchema#string

P932

2791370

http://www.w3.org/2001/XMLSchema#string